Compare Cassava Sciences Inc (FLNA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Global X NASDAQ 100 Covered Call ETF trades at $18.01. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | QYLD | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $18.52 |
52-Week Low | $1.09 | $16.46 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
QYLD trades at $18.06, down 1.69% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's strategy of selling covered calls on the Nasdaq-100 generates high dividend yields, but financial ratios like P/E and ROE are not applicable due to its structure. Recent news highlights concerns over long-term NAV erosion despite attractive income.
The outlook for QYLD centers on its high yield for income-focused investors, but risks include underperformance in strong bull markets and capital depreciation. Analyst sentiment is mixed, emphasizing the trade-off between steady dividends and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
